Lunit and Summit Therapeutics have entered a research agreement to assess the Lunit SCOPE IO AI pathology platform for analysing the tumour microenvironment across immuno-oncology programmes ...

Numerous types of equity deals involving Chinese biotech, including the popular NewCo model, will be impacted by the proposed rule.

GSK's likely blockbuster-to-be led to a fifth of patients having undetectable viral levels in clinical trials.

With the AI revolution underway, sustainability is now a key consideration for pharma companies building and utilising data centres.

AI Proteins and Astellas Innovation Management have signed a research collaboration and licence deal to discover and develop miniprotein therapeutics.

Gilead plans to develop HCXT-2001 both as a monotherapy and in combination with its own IBD hopeful, emvistegrast.

Celltrion has acquired exclusive global development and commercialisation rights to Kaigene's investigational monoclonal antibody, KG013, in a deal worth up to $580m.

Boehringer Ingelheim and Microsoft have entered into a strategic collaboration to examine the use of AI in clinical research, beginning with studies in lung health.

Following its provisional blessing in IgAN, AstraZeneca's Ultomiris is now indicated for use in six conditions.

Fenwick partners Chelsea Anderson and Noah Solowiejczyk outline how prediction markets will impact how biotechs operate.

Consolidating complicated supply chains with trusted providers reduces governance, sharpens cost and emissions insight, and creates a more resilient, coordinated network.

At CPHI Milan 2026, pharma leaders examined how AI can accelerate formulation, process development, maintenance, and quality management—without compromising data security or human oversight.